Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small ...

Engineered nanoparticles can improve cancer immunotherapy by delivering drugs, antigens, and genetic payloads with greater ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering ...

A new Phase I clinical trial provides proof of concept for a potential therapy for treatment-resistant cancers, particularly ...

Issued on behalf of GT Biopharma, Inc.After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, ...

Detailed price information for Geovax Labs Inc (GOVX-Q) from The Globe and Mail including charting and trades.

Roche was granted a Phase 3 clinical trial waiver by CDSCO last year for the Indian launch of Tecentriq SC. The Swiss pharma ...

A phase 2 trial evaluated the efficacy of nivolumab added to brachytherapy, external beam radiation therapy, and ADT in men with high-risk grade group 5 prostate cancer.

CD73 inhibitors present significant opportunities in cancer immunotherapy by reversing immunosuppression in tumors and enhancing immune response. Novel antibodies, RNA, and small molecules are in ...

LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech ...

A new blood test profiles tumor microenvironment ecotypes via cell-free DNA methylation—correlating with biopsy findings and ...

GPC3-targeted immunotherapies present key market opportunities in hepatocellular carcinoma treatment. With GPC3 being selectively expressed in HCC, there's potential for novel therapies like CAR ...